The stock of Evelo Biosciences Inc. (NASDAQ:EVLO) last traded at $3.23, up 39.83% from the previous session.
EVLO stock price is now 16.21% away from the 50-day moving average and -83.86% away from the 200-day moving average. The market capitalization of the company currently stands at $18.09M.
With the price target maintained at $12, Chardan Capital Markets recently Upgraded its rating from Neutral to Buy for Evelo Biosciences Inc. (NASDAQ: EVLO).
In other news, Bodmer Mark, CSO, President of R&D sold 22,571 shares of the company’s stock on May 23. The stock was sold for $3,201 at an average price of $0.14. Upon completion of the transaction, the CSO, President of R&D now directly owns 262,557 shares in the company, valued at $0.85 million. An SEC document containing details of the transaction can be found on the SEC’s website. On May 08, CSO, President of R&D Bodmer Mark sold 68,014 shares of the business’s stock. A total of $8,536 was realized by selling the stock at an average price of $0.13. This leaves the insider owning 285,128 shares of the company worth $0.92 million. Insiders disposed of 176,963 shares of company stock worth roughly $0.57 million over the past 1 year. A total of 0.10% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in EVLO stock. A new stake in Evelo Biosciences Inc. shares was purchased by JEFFERIES FINANCIAL GROUP INC. during the first quarter worth $12,000. MAN GROUP PLC invested $9,000 in shares of EVLO during the first quarter. In the first quarter, VIRTU FINANCIAL LLC acquired a new stake in Evelo Biosciences Inc. valued at approximately $4,000. AVANTAX PLANNING PARTNERS, INC. acquired a new stake in EVLO for approximately $2,000. AFFINITY CAPITAL ADVISORS, LLC purchased a new stake in EVLO valued at around $2,000 in the second quarter.
With an opening price of $2.5000 on Monday morning, Evelo Biosciences Inc. (NASDAQ: EVLO) set off the trading day. During the past 12 months, Evelo Biosciences Inc. has had a low of $0.49 and a high of $65.80. The fifty day moving average price for EVLO is $2.8052 and a two-hundred day moving average price translates $19.8277 for the stock.
The latest earnings results from Evelo Biosciences Inc. (NASDAQ: EVLO) was released for Mar, 2023. According to the Biotechnology Company, earnings per share came in at -$4.6, missing analysts’ expectations of -$3.16 by -1.44. This compares to -$0.56 EPS in the same period last year. The company reported revenue of $24.9 million for the quarter, compared to $28.74 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -13.36 percent.
Evelo Biosciences Inc.(EVLO) Company Profile
Evelo Biosciences, Inc., a clinical-stage biotechnology company, focuses on discovering and developing oral medicines that act on immune cells in the small intestine with systemic effects. It is developing EDP1815, a whole-microbe product candidate, which has completed a Phase 2 trial for the treatment of psoriais; and is in Phase 2 clinical trial for the treatment of atopic dermatitis. The company is also developing EDP1867, a non-live pharmaceutical preparation for single strain of Veillonella parvula, which is in Phase 1b clinical trial; EDP2939, an investigational oral biologic for the potential treatment of inflammatory diseases; and EDP1908, a product candidate for oncology. Evelo Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
